Zinger Key Points
- Shares surged over 80% after the company announced clinical trial results showing its unbuzzd™ supplement significantly accelerates alcohol.
- The study found unbuzzd lowered blood alcohol levels 40% faster, improved alertness, and reduced hangover symptoms.
- Get Wall Street's Hottest Chart Every Morning
Shares of Quantum BioPharma Ltd. QNTM soared more than 80% on Tuesday after the company announced positive clinical trial results for its dietary supplement, unbuzzd, which accelerates the reduction of blood alcohol concentration.
What To Know: The double-blind, placebo-controlled study showed that unbuzzd significantly reduced blood alcohol levels, with most participants seeing a 40% faster drop within 30 minutes of consumption. The supplement also improved alertness, stabilized the physiological effects of alcohol intoxication and reduced hangover symptoms, with no reported side effects.
The trial included male and female participants aged 21 to 43, and the results indicated statistically significant improvements in mental alertness and cognitive function. Participants also reported fewer symptoms of mental fatigue and physical impairment, with a 67% reduction in headache severity at four and eight hours post-consumption.
Quantum BioPharma's Vice President of Clinical and Scientific Affairs, Dr. Andrzej Chruscinski, said the study confirms the supplement's effectiveness in mitigating the acute effects of alcohol intoxication. CEO Zeeshan Saeed emphasized its potential for responsible alcohol consumption.
QNTM Price Action: Quantum BioPharma shares were up 82.4% at $5.80 at the time of writing, according to Benzinga Pro.
Read Next:
Image Via Shutterstock.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
